A randomized double-blind, double dummy, placebo and lorazepam-controlled, 4-way cross-over study to evaluate the pharmacodynamics of single oral doses of BNC210 in healthy young male subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2011
At a glance
- Drugs BNC 210 (Primary) ; Lorazepam
- Indications Anxiety disorders; Panic symptoms
- Focus Pharmacodynamics
- 01 Sep 2011 Results reported in a Bionomics media release, and to be presented at the European College of Neuropsychopharmacology (ECNP).
- 30 Mar 2011 Positive results have been reported in a Bionomics media release; the company anticipates that data from this trial will be presented at a major scientific conference later this year.
- 30 Mar 2011 Status changed from recruiting to completed.